Explore daily insights on
ADC Therapeutics falls sharply on blood cancer drug safety concerns in Phase 3 trial
- ADC Therapeutics shares fell sharply after a Phase 3 study of its lymphoma drug Zynlonta raised serious safety concerns.
- The stock fell to approximately $1.50 on June 4, 2026, following the trial announcement on June 3.
- The trial showed higher rates of serious adverse events and Grade 5 events in the Zynlonta arm, which analysts highlighted as potentially difficult for physicians, patients, and regulators to accept.
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 3 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
ADCT fell approximately 51% on June 4, 2026, following announcement of Phase 3 LOTIS-5 topline data on June 3. The trial showed serious adverse events in 49.0% of the Zynlonta plus rituximab arm versus 34.5% in the control arm, and Grade 5 treatment-emergent adverse events in 13.2% versus 4.6%. The trial met its primary endpoint of progression-free survival but showed no overall survival benefit.